Arcturus Therapeutics Holdings (ARCT)
(Delayed Data from NSDQ)
$20.61 USD
-0.41 (-1.95%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $20.63 +0.02 (0.10%) 6:46 PM ET
1-Strong Buy of 5 1
D Value A Growth D Momentum B VGM
Brokerage Reports
Arcturus Therapeutics Holdings Inc. [ARCT]
Reports for Purchase
Showing records 41 - 60 ( 142 total )
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
4Q20 Recap; Approaching Key Moment As ARCT-021 Phase 2 SARS-CoV-2 Trial Nears Top-Line Readout; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
IP Acquisition Bolsters mRNA Manufacturing Ahead of Potential LUNAR-COV19 Approval in 2H21
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Phase 1 Data on COVID-19 Vaccine Disappoints; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Recap: Deep Selloff Betrays a Myopic and Misguided View That "Winner-Takes-All" in COVID Vaccines
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
A Good Day for Vaccines, A Good Day for Arcturus
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Downpayment Received, Now It Is Binding
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Critical Milestones in 4Q20 with First-in-Human Data for Both ARCT-810 and ARCT-021; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E